# OnCo record cd80 (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/cd80/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "cd80" ;
  schema:name "CD80 (B7-1)"@en ;
  schema:alternateName "B7-1"@en, "B7.1"@en, "CD28LG"@en, "CD80 molecule"@en, "CD80" ;
  schema:description "B7-1 is a molecule on antigen-presenting cells that gives T cells their go signal through CD28, but it also feeds the CTLA-4 brake and can pair with PD-L1. Anti-PD-L1 antibodies such as sugemalimab and adebrelimab are built to stop PD-L1 binding both PD-1 and B7-1."@en ;
  schema:url <https://onco.cc/targets/cd80/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1700>, <https://www.uniprot.org/uniprotkb/P33681/entry>, <https://www.ncbi.nlm.nih.gov/gene/941> ;
  onco:tag "wave5-target" ;
  onco:targetClass "checkpoint" ;
  schema:sameAs <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1700>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000121594>, <https://www.uniprot.org/uniprotkb/P33681/entry>, <https://www.ncbi.nlm.nih.gov/gene/941> ;
  onco:related <https://onco.cc/drugs/adebrelimab/>, <https://onco.cc/drugs/sugemalimab/>, <https://onco.cc/drugs/tqb2450/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/targets/cd28/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/pdl1/> ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/cancer-immunity-cycle/> .